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Our hypothesis in this study was that in vitro disappearance of isoflavones from fecal or cecal contents
of Golden Syrian hamsters paralleled the apparent absorption of these compounds, comparable with
previous findings from in vitro human fecal incubations. Two studies were conducted to test this idea:
one on in vitro fecal (study 1, n ¼ 20/sex) and the other on in vitro cecal contents (study 2, n ¼ 10/sex)
ability to degrade isoflavones. According to HPLC analysis, urinary isoflavone excretion was
significantly less by 2–4 fold in males compared with females in both studies. Fecal isoflavone excretion
was not significantly different between sexes or isoflavones (study 1) and was <0.5% of ingested dose.
In vitro anaerobic fecal isoflavone degradation rate constants from study 1 were minimal with no
significant correlation between urinary and fecal isoflavone excretion. However, in vitro anaerobic cecal
isoflavone degradation rate constants (study 2) were greater and significantly correlated with urinary
excretion of daidzein (R ¼ 0.90; p ¼ 0.01) and genistein (R ¼ 0.93; p ¼ 0.004), but not glycitein
(R ¼ 0.50; p ¼ 0.3). Both male and female hamsters showed a pattern of urinary isoflavone excretion
similar to that found in humans (daidzein > genistein). Hamster in vitro cecal isoflavone degradation
rate constants seemed to be analogous to human in vitro fecal isoflavone degradation rate constants for
genistein and daidzein. The sex difference in isoflavone excretion in hamsters and the instability in
glycitein excretion across studies coupled with the paucity of human data on this isoflavone deserve
further investigation.
Introduction
Dietary isoflavones are found mainly in soybeans and soy prod-
ucts.1 Their chemical structure is estrogen-like.2 They prevent
mammary carcinogenesis in rodents,3 but the health effects of
these compounds are highly variable among individuals and their
bioavailability is not well understood. In humans, 1–50% of the
ingested dose of isoflavones is excreted in the urine, mostly as
glucuronide conjugates, whereas less than 1% is recovered in the
feces. The great proportion of isoflavones not recovered or dis-
appearing has been linked with microbial metabolism and
degradation of these compounds.4,5 When isoflavones were incu-
bated in vitro with human feces, they disappeared within 48 h.
Human fecal isoflavone degradation rate constants sorted into
statistically significant clusters: high, moderate or low.6 Asian
women who were low isoflavone degraders had threefold greater
urinary genistein excretion than did Asian high isoflavone
degraders or Caucasian low or high isoflavone degraders and
more rapid gut transit time (GTT6). Thus in vitro fecal isoflavone
degradation and GTT interacted in predicting apparent iso-
flavone absorption in women. Also, in vitro human fecal iso-
flavone degradation rate constant predicted urinary excretion of
isoflavones from ingestion of soy milk in 10 human subjects.7
Animal models need to be established to facilitate long term
study of the role of isoflavone bioavailability in dietary modu-
lation of chronic diseases. Golden Syrian hamsters deserve
attention because of the hypocholesterolemic action of iso-
flavones in this species.8 Bravo et al.9 showed that human and
hamster cholesterol metabolism is similar. Hypocholesterolemic
effects of a diet containing 25% soy protein fed to 40 hamsters for
4 weeks was only observed in animals clustering statistically as
high isoflavone excreters.10 This finding highlights the impor-
tance of more detailed studies of isoflavone bioavailability in
hamsters, with a focus on gut microbial metabolism as a deter-
minant of isoflavone bioavailability. Our hypothesis in this study
was that disappearance of isoflavones from in vitro incubations
of fecal or cecal contents in hamsters predicted isoflavone
bioavailability as seen previously for in vitro human fecal incu-
bations. To test this hypothesis, two studies were conducted on
in vitro fecal or cecal contents and their ability to degrade
isoflavones.
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Materials and methods
Chemicals and diets
Novasoy (ADM, Decatur, IL) was fed to hamsters as an iso-
flavone source; isoflavone composition was determined by
HPLC.1 Total isoflavone concentration was 963 mmol kg1 diet
and daidzein, genistein and glycitein were 36%, 52% and 12% of
total isoflavones respectively. The casein-based isoflavone-con-
taining diet was formulated to contain 0.1% cholesterol and
saturated fat from coconut oil (10% by weight of diet).8 Iso-
flavones used for fecal and cecal in vitro incubations were
synthesized chemically according to Chang et al.11 and Lang’at-
Thoruwa et al.12 Other chemicals used for isoflavone extraction
and analysis were purchased from Fisher Scientific (Pittsburg,
PA) and Sigma Chem. Co. (St. Louis, MO).
Animals and study designs
The animal experimental protocols for both studies were
approved by the Iowa State University Institutional Animal Care
and Use Committee.
Study 1. 20 male and 20 female Golden Syrian hamsters
(4 weeks of age), were obtained fromHarlan-Teklad (Madison,
WI), housed individually in a temperature-controlled room
(23 C) with a 12 h light : dark cycle and fed rodent chow for
2 weeks. Hamsters were then fed the isoflavone, casein-based diet
ad libitum for 2weeks andput inmetabolic cages for 24h to collect
urine and feces. Body weight and food intake were monitored
daily. Isoflavone analysis was performed within 48 h after urine
collection and animals euthanized under CO2 less than 48 h after
isoflavone extraction and HPLC analysis of all urine samples.
During that time, animals were fed the same isoflavone/casein-
based diet, which was withdrawn 12 h before euthanizing them
under CO2. After ranking animals from lowest to highest iso-
flavone excretion and selecting only animals that were high or low
excreters of all 3 isoflavones, then performing statistical cluster
analysis to confirm groupings, contents from the large intestine of
the 4 highest and 4 lowest urinary excreters of isoflavones were
collected for in vitro fecal incubations. Urine could not be
obtained from onemale and one female over the 24 h inmetabolic
cages. Those hamsters were withdrawn from the experiment.
Study 2. 10 male and 10 female Golden Syrian hamsters
(4 weeks of age), were obtained as above. Protocols and design
of this study was similar to study 1, except that cecal instead of
fecal contents from the three highest and lowest urinary excreters
were collected for in vitro incubations, again, after selecting
animals either high or low in excretion of all 3 isoflavones and
verifying grouping by statistical cluster analysis. In addition,
only urinary, but not fecal isoflavone analysis was performed in
this study. Urine was not collectable from one male over 24 h in
the metabolic cage. That hamster was withdrawn from the
experiment.
Urinary isoflavone analysis
Isoflavone extraction from urine samples was done following
a modified protocol established by Zhang et al.13 Five mL urine
were incubated with 50 mL b-glucuronidase-sulfatase (Sigma, St.
Louis, MO) at 37 C for 20 h to obtain isoflavone aglucons.
Fifty mL 2,4,40-trihydroxydeoxybenzoin (THB) was added as
internal standard. Incubation mixtures were loaded on Extrelut
(TM) QE columns (EM Science, Gibbstown, NJ) and extracted
with ethyl acetate. The eluent was collected, dried using a rotary
evaporator (Buch€ı, Flawil, Switzerland) and dissolved in 9.8 mL
of 20% ethanol and 0.2 mL of 1 N HCL. Five mL of this solution
was loaded onto a pre-wetted Sep-pak C18 cartridge (Waters,
Rainin, Woburn, MA), washed twice with 2 mL of distilled
deionized water and eluted with 2 mL of 80% methanol. Samples
were stored at 4 C until HPLC analysis (12). Urinary isoflavone
excretion was expressed as a percentage of the dose ingested over
24 h, to normalize data across variations in food intake and body
weight.
Fecal isoflavone analysis
Fecal excretion of isoflavone was measured using 2 g of
ground fecal sample mixed with 10 mL acetonitrile and 2 mL of
0.1 mol L1 HCl. The mixture was stirred for 3 h, then filtered
through No. 1 Whatman filter paper. The eluent was collected in
a round bottom flask and evaporated using a roto-evaporator
(Buch€ı, Flawil, Switzerland). The residue was dissolved in 2 mL
ethanol, 7.8 mL ultrapure water and 200 mL of 1 mol L1 HCl.
Five mL were loaded on a pre-wetted Sep-Pak C18 cartridge
(Waters, Rainin, Woburn, MA), washed with 2 mL of distilled
deionized water and eluted with 2 mL of 80% methanol. Samples
were stored at 4 C until HPLC analysis.
In vitro fecal and cecal incubations: isoflavone analysis
At the end of each study, animals were euthanized under CO2
and the content of the colon (study 1) or cecum (study 2) of the
3 or 4 highest and lowest urinary isoflavone excreters placed in
15 mL of anaerobic brain heart infusion media (BHI, Fisher,
Chicago, IL). BHI was prepared with 50 mL 8% sodium bicar-
bonate/L as a buffer and 20 mL 1.25% cysteine sulfide (Sigma, St
Louis, MO)/L as an oxygen indicator. The BHI containing fecal
or cecal contents was vortexed for 15 s and 5 mL mixed with
20 mL BHI media containing a final concentration of 50 mmol
each of daidzein, genistein and glycitein/L. Duplicate tubes were
incubated for each fecal or cecal sample obtained as well as
a negative control. After adding isoflavone, each tube was then
vortexed for 10 s and duplicate samples taken immediately
afterwards and frozen at 60 C to measure isoflavone concen-
tration at time 0. Tubes were placed at 37 C and isoflavone
concentrations over time were measured in duplicate samples
from each tube at 3, 6, 9 and 12 h. All the samples were stored
at 60 C until isoflavone extraction and HPLC analysis. Incu-
bation tubes were maintained anaerobically at all times to
preserve bacterial quality.
Statistical analysis
Statistical analysis was performed using SAS (SAS Institute,
version 6.12; 1998, Cary, NC). Urinary isoflavone excretion
phenotypes were established using a statistical cluster analysis.
Fecal and urinary isoflavone excretion was compared between
clusters by one-way ANOVA and correlations between urinary
































and fecal isoflavone excretion and between the different iso-
flavones for their excretion were determined by regression anal-
ysis. All results were considered significant at p < 0.05.
Results
Body weight and food intake
Study 1. Initial mean body weights were similar (p ¼ 0.1)
between males (122  9 g) and females (117  10 g). Despite
similar food intakes of males and females (7.1 0.7 g/d and 7.3
0.5 g/d, respectively; p ¼ 0.3), females gained significantly more
weight (1.0  0.3 g/d) than did males (0.7  0.2 g/d; p ¼ 0.01).
Study 2. Mean initial body weight was similar (p ¼ 0.09)
between males (114  4 g) and females (119  7 g). Food intakes
of males (7.6  0.5 g/d) and females (7.7  0.4 g/d) were similar
(p¼ 0.4). Mean daily body weight gain was significantly different
(p ¼ 0.001) between males (0.8  0.2 g/d) and females
(1.1  0.1 g/d).
Urinary isoflavone excretion
Study 1. Males and females differed greatly in urinary excre-
tion of isoflavones over 24 h (Fig. 1A). In males, daidzein and
glycitein excretion were similar (18  8% vs. 16  6% ingested
dose; p ¼ 0.3), whereas urinary excretion of genistein was
significantly less (8  6% ingested dose) than that of daidzein
(p < 0.001) or glycitein (p < 0.001). In females, mean urinary
glycitein and genistein excretion was similar (31  11% vs. 27 
12% ingested dose; p ¼ 0.2), whereas mean urinary excretion of
daidzein was significantly greater (44  14% ingested dose) than
that of glycitein (p ¼ 0.003) and genistein (p < 0.001).
Overall, males had less urinary isoflavone excretion of daidzein
(p < 0.001), glycitein (p < 0.001) and genistein (p < 0.001) than
did females. Clustering of animals as high or low excreters based
on urinary isoflavone excretion showed that females were mostly
high excreters whereas males were mostly low excreters (Fig. 2;
data not shown for daidzein or glycitein). Regardless of
sex, urinary daidzein correlated with both glycitein and genistein
(r¼ 0.97 and r¼ 0.96; p < 0.001). Urinary glycitein and genistein
were also correlated (r ¼ 0.97; p < 0.001).
Study 2. In males, urinary daidzein and glycitein excretion
were similar over 24 h (14  8% vs. 11  5% ingested dose;
p ¼ 0.4), whereas urinary genistein excretion was significantly
less (7  5% ingested dose) than that of daidzein (p ¼ 0.03) but
not glycitein (p ¼ 0.07). In females, mean urinary excretion of
glycitein and genistein was similar (18  8% vs. 16  9% ingested
dose; p ¼ 0.54), whereas mean urinary excretion of daidzein was
significantly greater (30  13% ingested dose) than glycitein
(p ¼ 0.03) or genistein (p ¼ 0.01). Males had less urinary iso-
flavone excretion than did females for each isoflavone (Fig. 1B).
As observed in study 1, clustering of animals as high and low
urinary isoflavone excreters showed that females were mostly
high excreters whereas males were mostly low excreters (Fig. 3;
data shown only for genistein).
Study 1 versus study 2.Males excreted significantly less urinary
isoflavones than did females in both studies (Fig. 1). The pattern
of urinary isoflavone excretion in females was the same in both
studies (daidzein > glycitein ¼ genistein). Urinary isoflavone
excretion in males was not statistically different between study
Fig. 1 Comparison of urinary excretion levels between in male and
female Golden Syrian hamsters; A) Study 1, B) Study 2, male,, female
-). Different letters indicate significant differences, p < 0.05.
Fig. 2 Ranking and cluster analysis of individual genistein urinary
excretion values in male and female Golden Syrian hamsters (study 1).
Grey bars indicate male hamsters; black bars indicate female hamsters;
horizontal stripes indicate animals selected for fecal in vitro incubations.
































1 and 2 for daidzein (p ¼ 0.15) or genistein (p ¼ 0.65). Glycitein
excretion in males was similar to that of daidzein but not gen-
istein in study 1 but did not differ from either daidzein or gen-
istein in study 2.
Fecal isoflavone excretion
In study 1, fecal isoflavone excretion was analyzed for each
animal over 24 h with less than 0.5% of ingested isoflavones
present in feces. There was no significant difference between fecal
isoflavones within sex or for the same isoflavone between sexes
(data not shown). Fecal isoflavone excretion was not significantly
correlated with urinary isoflavone excretion (regardless of sex)
for daidzein (r ¼ 0.35; p ¼ 0.24), glycitein (r ¼ 0.16; p ¼ 0.6) and
genistein (r ¼ 0.29; p ¼ 0.34). But among the three isoflavones,
fecal daidzein excretion correlated significantly with that of
glycitein (r ¼ 0.92; p < 0.001) and genistein (r ¼ 0.91; p < 0.001);
fecal glycitein correlated with genistein (r ¼ 0.86; p < 0.001).
Correlation between in vitro anaerobic fecal degradation and urinary
excretion of isoflavones
From study 1, feces from 4 high urinary excreters (M1, F7, F9,
F14) and 4 low urinary excreters (M20, M16, M18, F4) were
assessed for in vitro isoflavone degradation rate. Animals were
selected based on their combined urinary excretion of the three
isoflavones. Mean in vitro fecal isoflavone degradation rate
constants did not differ between high and low urinary excreters
of daidzein, glycitein or genistein (Table 1). Across urinary iso-
flavone excretion phenotypes, mean fecal in vitro degradation
rate of genistein (0.28  0.14 h1; n ¼ 8) was significantly greater
than that of daidzein (0.012  0.006 h1; p < 0.001) or glycitein
(0.03  0.016 h1; p < 0.001). In addition, overall mean fecal
degradation rate of daidzein was significantly less than that of
glycitein (p ¼ 0.008). Correlations between in vitro fecal degra-
dation rate constants and urinary excretion were not statistically
significant for daidzein (r ¼ 0.49; p ¼ 0.21), glycitein (r ¼ 0.31;
p ¼ 0.44) or genistein (r ¼ 0.33; p ¼ 0.41). Correlations between
in vitro fecal degradation rate constants and fecal isoflavone
excretion were not significant for daidzein (r ¼ 0.5; p ¼ 0.19),
glycitein (r ¼ 0.28; p ¼ 0.49) or genistein (r ¼ 0.16; p ¼ 0.69).
Correlation between in vitro cecal degradation and urinary excretion
of isoflavone
In study 2, cecal contents of 3 high (F1, F9, M5) and 3 low
urinary isoflavone excreters (M2, M8, M9) were assessed for
in vitro isoflavone degradation. Animals were selected based on
their combined urinary excretion of the three isoflavones. Mean
cecal degradation rate constants were significantly different
between high and low urinary excreters of daidzein and genistein,
whereas mean cecal glycitein degradation rate constants of high
and low urinary isoflavone excreters did not differ (Table 1). For
both high and low urinary isoflavone excreters, genistein was
significantly more degraded in vitro than daidzein (p ¼ 0.003
(high), p < 0.001 (low)) or glycitein (p ¼ 0.01 (high), p ¼ 0.001
(low)) whereas cecal degradation of glycitein and daidzein did
not differ (p ¼ 0.07 (high), p ¼0.10 (low)). Correlations between
in vitro cecal degradation rate constants and urinary excretion
were statistically significant for daidzein (r ¼ 0.90; p ¼ 0.01)
and genistein (r¼ 0.93; p¼ 0.004), but not for glycitein (r¼ 0.50;
p ¼ 0.3, Fig. 4, data shown only for genistein).
Discussion
This study examined the relevance to humans of Golden Syrian
hamsters as a model for gut microbial influences on the apparent
absorption of isoflavones. Despite initial body weight and similar
daily food intake, females gained significantly more weight on
a daily basis compared with males. This unusual sexual dimor-
phism is documented but not well explained, and could be an
obstacle to the use of hamsters as models for human metabolic
conditions.
Urinary excretion of isoflavones showed surprising differences
within and between studies. Whereas a similar pattern was
observed between studies in females (daidzein > glycitein ¼
genistein), urinary isoflavone excretion was less in study 2
compared to study 1 for all isoflavones. Study 1 may have more
relevance than study 2 due to the greater numbers of individuals.
But, 50% of females in study 2 were low urinary isoflavone
excreters (Fig. 3) compared with 25% of females in study 1
(Fig. 2), which may have explained the lesser overall isoflavone
excretion observed in study 2 (Fig. 3). Although gut microbes
were not studied in these hamster studies, human studies6 suggest
that the greater proportion of low urinary isoflavone excreters in
study 2 may be due to differences in gut microbes between
studies. Although urinary excretion of glycitein in males shifted
from being similar to daidzein and greater than genistein in study
1 to not differing from the other isoflavones in study 2, urinary
daidzein excretion was greater than that of genistein in both sexes
and both studies. A similar pattern of greater urinary daidzein
than genistein was observed in humans across several bioavail-
ability studies.12–14
Sex differences in isoflavone excretion were observed in both
studies, with males being lesser urinary excreters of all three
isoflavones compared with females (Fig. 1). Zhang et al.13
showed 20% less urinary excretion of isoflavones from single
doses of soymilk or soygerm in 7 men than in 7 women. During
Fig. 3 Ranking and cluster analysis of individual genistein urinary
excretion values in male and female Golden Syrian hamsters (study 2).
Grey bars indicate male hamsters; black bars indicate female hamsters;
horizontal stripes indicate animals selected for fecal in vitro incubations.
































a one month feeding study, 6 women excreted 24 and 66% of the
ingested doses of genistein and daidzein, respectively, whereas 6
men excreted 15 and 47% of ingested dose of genistein and
daidzein, respectively.14 After one month, women excreted 14%
less daidzein and 45% less genistein in urine than at time 0,
whereas in men, urinary isoflavone excretion was stable. Urinary
isoflavones in women were within the same range observed in
female hamsters (Fig. 1) for daidzein (60 vs. 40% of ingested
dose) and genistein (20 vs. 20% ingested dose).15 Urinary
isoflavones for men15 and male hamsters seemed different for
daidzein (47 vs. 15% ingested dose) but were fairly similar for
genistein (15 vs. 8% ingested dose). Thus, urinary excretion
was more similar to humans for female than for male hamsters.
But Wiseman et al.16 found no sex differences in daidzein and
genistein excretion in 19 men and 19 women after 10 weeks of soy
intake. Overall, human sex differences in isoflavone excretion
seem less pronounced than that observed in hamsters.
The present data in male hamsters were similar to that of
another rodent model. King17 compared the bioavailability of
daidzein and genistein in male Wistar rats fed a soy extract
providing 74 mmol genistein and 77 mmol daidzein/kg body
weight. Urinary excretion over 48 h was 17  1% (15% in the
present study) and 12  1% (8% here) of ingested daidzein and
genistein, respectively, whereas fecal excretion was 2  1% and
3  1% of ingested dose of these isoflavones. Given the highly
variable isoflavone excretion reported across human
studies,4,13,14,16 the overall apparent absorption of isoflavones in
hamsters seems generally consistent with that seen in humans.
Fecal isoflavone excretion in study 1 did not show sex differ-
ences, with very low levels of excretion (0.1 to 0.5% ingested
dose). Up to 3.5% of ingested isoflavone dose was found in fecal
sample from rats17 whereas women who excreted more urinary
isoflavones also excreted greater fecal isoflavones (up to 6% of
ingested dose) compared with lower urinary excreters.4 Thus, we
expected greater fecal isoflavones in female than in male
hamsters. But there was no significant sex difference in fecal
isoflavones, nor was there a significant correlation between fecal
and urinary excretion of individual isoflavones. Positive corre-
lations were found between isoflavone excretion in human urine
and feces.4,13 Because human fecal18 and hamster cecal isoflavone
degradation rate constants were similar, but limited hamster
fecal isoflavone degradation also occurs, the seemingly lesser
fecal recovery of isoflavones in hamsters than in humans prob-
ably results from combined cecal and fecal isoflavone
disappearance.
In vitro anaerobic fecal degradation of isoflavones may predict
apparent absorption of isoflavones in humans.4,6,13,19,20 Subjects
who had high in vitro isoflavone degradation were low urinary
excreters whereas those who degraded lesser amounts of iso-
flavone in vitro excreted more urinary isoflavones. Our hypoth-
esis that in vitro fecal isoflavone degradation in hamsters would
correlate with urinary excretion pattern was incorrect. Fresh
hamster feces collected from the large intestine of high and low
urinary isoflavone excreters showed low in vitro isoflavone
degradation rate constants, not exceeding 0.015, 0.030 and 0.300
for daidzein, glycitein and genistein respectively, whereas in
humans, in vitro fecal isoflavone degradation rate constants were
0.299 and 0.400 for daidzein and genistein, respectively.19 Only
genistein degradation seemed to reach levels that indicated
significant hamster fecal bacterial isoflavone degradation, which
may have partly explained the lesser apparent absorption of
genistein, but the absence of correlation with urinary isoflavone
excretion and very low in vitro fecal degradation of daidzein and




excretion (% ingested dose)
In vitro fecal isoflavone
degradation rate constant (h1)
In vitro cecal isoflavone
degradation rate (h1)
High (study 1) 4 Daidzein 52.7  17.0* 0.10  0.008
Glycitein 38.1  14.0* 0.030  0.018
Genistein 33.7  14.2* 0.27  0.14
Low (study 1) 4 Daidzein 10.8  1.8 0.015  0.004
Glycitein 8.1  1.0 0.031  0.016
Genistein 3.5  1.0 0.30  0.16
High (study 2) 3 Daidzein 45.7  13.1* 0.03  0.02*
Glycitein 28.9  6.7* 0.21  0.11
Genistein 34.1  10.1* 0.79  0.07*
Low (study 2) 3 Daidzein 8.2  1.6 0.12  0.03
Glycitein 7.5  2.3 0.29  0.12
Genistein 5.9  1.2 1.38  0.16
a Within a column, study and isoflavone, an asterisk (*) indicates a significant difference between isoflavone excretion phenotypes, p < 0.05.
Fig. 4 Correlation between genistein in vitro cecal degradation rate
constants and in vivo urinary excretion data between high (n¼ 3) and low
(n ¼ 3) urinary excreters (study 2).
































glycitein led us to the conclusion that in vitro fecal degradation
assay was of limited use to predict isoflavone bioavailability in
hamsters. Cecal isoflavone degradation in study 2 was apparently
greater than was fecal isoflavone degradation in study 1, and the
significantly lesser cecal degradation rates of daidzein and gen-
istein in 3 low degraders compared with 3 high degraders par-
alleled the significantly greater urinary isoflavone excretion in the
low degraders compared with the high degraders (Table 1).
Significant correlations were found between urinary isoflavone
excretion and in vitro cecal degradation rates of daidzein and
genistein, similar to that seen for human urinary isoflavone
excretion and in vitro fecal isoflavone degradation. Therefore, in
vitro cecal isoflavone degradation rather than fecal degradation
in hamsters is more metabolically equivalent to human in vitro
fecal isoflavone degradation.
In vitro cecal degradation of glycitein was not predictive of
urinary glycitein excretion. The cecal glycitein degradation rate
constants were more variable than the other cecal isoflavone
degradation rate constants and the difference between the two
excretion phenotypes in urinary excretion of glycitein was less
than that seen for the other two isoflavones. This suggests
different hamster gut microbial dynamics for glycitein degrada-
tion than for the degradation of the other isoflavones. In one
human subject, we found that fecal glycitein degradation rate but
not degradation rate constants of other isoflavones changed
markedly over one month (data not shown). The limited human
bioavailability data on glycitein and these findings in hamsters
support the need for further investigation of this isoflavone in
both species.
Conclusions
The present study indirectly investigated the concept that gut
microbial degradation of isoflavones predicts isoflavone
bioavailability by associating in vitro fecal and cecal degradation
rate constants of isoflavones with urinary isoflavone excretion in
hamsters. This approach showed similar patterns of apparent
absorption of the two major isoflavones, daidzein and genistein,
as found in humans, in whom vitro fecal degradation of iso-
flavones was compared with urinary isoflavone excretion,6,7,19,20
insofar as hamster cecal isoflavone degradation was similar to
human fecal isoflavone degradation in predicting apparent iso-
flavone absorption. The implication of this finding is that
prescreening hamsters for predictors of apparent isoflavone
absorption (e.g., gut microbial species yet to be determined) may
facilitate exploration of the long term health effects of interin-
dividual variation in isoflavone uptake,10 and related
compounds, with a strong likelihood of developing health
concepts transferrable to human circumstances.
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